The advantages of pharmaceutical internationalization business clearly create an integrated platform

Gao Yiwen, President of China Pharmaceuticals, said in an exclusive interview with China Securities Journal that the company’s absorption of the merger of Tianfang Pharmaceutical and its asset injection has been completed, and the fundamentals have undergone tremendous changes. It will make full use of its international advantages and support the pharmaceutical industry. Create a platform-based integrated service provider that provides medical health products and services.
The advantages of international business are obvious. China Securities Journal: China's major pharmaceutical asset restructuring plan is more complicated. Which step has it taken now? After the completion of the restructuring, what impact will it have on the long-term development of listed companies?
Gao Yiwen: The major asset restructuring is divided into three parts. The first part is to absorb the merger of Tianfang Pharmaceutical, and the second part is to inject the equity of four pharmaceutical companies in the group. These two parts have been completed. The third part is supporting financing. The funds raised through non-public issuance will not exceed 990 million yuan, and will be completed within the year.
After the completion of the reorganization, the company became the only pharmaceutical listing platform of GM Group, which is conducive to the comprehensive and systematic integration of the pharmaceutical industry resources of major shareholders. At the same time, the company realizes resource sharing and builds comprehensive profitability by building a complete industrial chain. More fundamentally and in the long run, the reorganization has completely solved the problem of competition in the same industry. The company has the conditions for refinancing, which also lays a good foundation for the company to fully utilize the capital market to accelerate its development in the future.
China Securities Journal: Among the listed companies in the A-share pharmaceutical sector, the internationalization of Chinese medicine accounts for a relatively high proportion and is also a characteristic business of the company. Please tell us about the company's international business.
Gao Yiwen: In 1984, the former Ministry of Foreign Trade and Economic Cooperation established the China National Pharmaceutical and Health Products Import and Export Corporation, which governed the import and export of medicines and health products. This is the predecessor of Chinese medicine. Since then, the company has gradually changed from an industry-managed company to a business-oriented company. In 1999, he joined China General Technology (Group) Holding Co., Ltd. and became the core enterprise of the Group's development of the pharmaceutical industry. In 2004, the backdoor China Technology Trade was listed. In 2007, the listed company was renamed as China Medicine. During this period, the company initially realized the transformation from traditional pharmaceutical foreign trade enterprises to the pharmaceutical industry, and became one of the few similar enterprises with successful transformation.
At the end of 2011, General Technology Group launched the reorganization and integration of the pharmaceutical sector, realizing the overall listing of the general technology group's pharmaceutical sector.
The restructured Chinese pharmaceutical industry products contributed about 20-25 to the profits of listed companies. The business structure continued to be optimized and the quality of operations continued to improve. From the listing in 2004 to 2012, China's pharmaceutical business revenue increased nearly five times; net profit increased from 0.2 billion yuan to 340 million yuan, an increase of 17 times; the average annual profit growth of the main business profit after deducting investment income reached 46. The reorganization of industrial assets has greatly enriched the resource base of our international business and will further enhance the strength of international development.
China Securities Journal: What are the resources and characteristics of China's pharmaceutical internationalization business, and what development models are there?
Gao Yiwen: After nearly 30 years of international development, Chinese medicine has gradually accumulated a business foundation for further deepening the transformation. On the one hand, we have accumulated a good international business resources, and in terms of brand and reputation, we have goodwill that ordinary companies cannot match. Secondly, in terms of network and variety, there are about 6,000 suppliers of Chinese medicine, including about 1,500 foreign suppliers; there are about 8,000 existing customers, including about 2,000 foreign customers. These networks and varieties provide a solid foundation for us to introduce and go out.
On the other hand, we have initially realized the transition to a specialized medical and health product supply chain integrated service provider, forming a basic development model for international business. First of all, it is a market specialization model based on the business of Cuba and Venezuela. It actively participates in the improvement of basic medical conditions in the host country and provides a package of professional solutions, which has been widely recognized by overseas customers.
Secondly, the Chinese medicine industry is a typical product industry chain specialization model, focusing on natural medicine key products, forming a deep-level business model, establishing a whole process quality traceability management system, and establishing a solid strategic cooperation with key enterprises.
In addition, with the marketing and professionalization model of diagnostic and medical device import agents, a set of professional sales channels from overseas manufacturers to domestic terminals has been established.
China Securities Journal: In the current fierce competition, how can Chinese medicine continue to play its international advantages and lay a solid foundation for further development of the company?
Gao Yiwen: If the past 30 years of history is the 1.0 version of international development, we are now looking for an upgraded version 2.0. The overall goal is to build the company into a platform-based integrated service provider that provides pharmaceutical health products and services to the domestic and foreign markets, supported by the pharmaceutical industry.
The company will give more play to the role of investment in business development, and promote business stability and sustainability through investment cooperation at home and abroad. For example, we will implement a strategic cooperation framework agreement with the Cuban biotechnology and pharmaceutical industry group to explore the establishment of a joint venture company in the Cuban Special Economic Zone, relying on the raw material supply and technical support of the Chinese pharmaceutical industry system, based on the Cuban radiation Latin America, for the Caribbean More than 100 million people provide medicines.
In addition, upgrade from business to research and development. For example, in the case of chemical drugs, it will mainly introduce varieties that are mature in foreign SMEs and not listed in China, and cooperate with foreign pharmaceutical giants to cooperate with imitation or authorized imitation; in biopharmaceuticals, it will actively carry out cooperation with Cuban biotechnology and pharmaceutical industry group. Cooperation, with the advantage of Cuba in biopharmaceuticals, jointly carry out domestic registration of products and jointly develop the domestic market.
Controlling the whole industry chain of Chinese medicine China Securities Journal: Chinese medicine has ranked first in the domestic export of traditional Chinese medicines such as licorice and ginseng for many years. Recently, the company has frequently moved in the upstream planting field of traditional Chinese medicine. What is the idea?
Gao Yiwen: Recently, the company has obtained 40,000 mu of artificially planted land resources through a joint venture with the Bachu government of Xinjiang, and obtained the exclusive mining rights and exclusive acquisition rights of the last more than 1 million mu of wild licorice origin in China. The wholly-owned subsidiary, General Meikang, will also conduct in-depth cooperation by participating in the 10 shares of Jiayi Company and carrying out ginseng planting and acquisition. Jiayi Company is also the only ginseng planting company in the world with organic certification in the United States, Japan, Europe, America and China. Since 2004, the number of organic ginseng exports has ranked first in the world for nine consecutive years.
The natural medicine business of China Pharmaceutical has always been in the leading position in the industry. For many years, it has exported natural medicine primary processing products to the EU, Japan, South Korea and other countries. From the control of planting sources, we have established a complete product traceability system and quality control system. Taking pesticide residue detection as an example, we have more than 300 pesticide residue testing programs, and the product quality is in full compliance with and even higher than international standards.
While making strong natural drugs for foreign sales, the company is also actively promoting the domestic sales of key varieties of Chinese herbal medicines. It is hoped that through some strategic measures, the whole industry chain of key varieties such as licorice and ginseng will be built. Taking licorice as an example, resource shortage has become a worldwide problem. Overseas resources such as Central Asia are drying up. In recent years, prices have increased by an average of 20-30. In terms of ginseng, the quality and activity of Changbai Mountain ginseng is similar to that of Korean ginseng, but the price is only About a quarter of Korean ginseng, high-quality domestic ginseng will face a return to value. The industrial integration of Chinese medicine as a key variety of Chinese herbal medicines, in addition to considering commercial value, is also actively fulfilling the responsibility of central enterprises for the industry and society.

Oil Pump AC Fan Cooling System

Product Parameters
Pneumatic Driven Fan Bar Plate(plate-fin) Heat Exchanger Series

Features:
Aluminum bar plate fin structure, coupled with high-performance air pump motor and high-strength fan leaves, in the complex working conditions for a long time to work.

Application:
air compressor gas cooling.

Technical Parameters:
The displacement of the motor in the table is for reference only and can be adjusted according to the actual working conditions and requirements.
Motor in and out of the oil is bidirectional, the standard configuration for the suction type.
Maximum operating pressure: 100psi Best use pressure: 70psi Applicable temperature: -10 ℃ ~ 70 ℃

The noise value is a value at a distance of 1 m.

Oil Pump Ac Fan Cooling System,Ac Fan Cooling System,Air Conditioner Cooling Fan,Aluminum Hydraulic Oil Cooler

Xinxiang Zhenhua Radiator Co., Ltd. , https://www.thermictransfer.nl